Secondary Hyperparathyroidism

Calcifediol May Improve PTH Control, Nutritional Status

Jody A. Charnow November 12, 2011

PHILADELPHIA—Adequate doses of calcifediol can correct 25-hydroxyvitamin D deficiency and improve malnutrition-inflammation status in hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT), researchers reported at Kidney Week 2011.

Cinacalcet Plus Low-Dose Vitamin D Improves SHPT Treatment

Jody A. Charnow November 12, 2011

PHILADELPHIA—Cinacalcet plus low-dose vitamin D provides a more effective approach to treating secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients, according to findings presented at Kidney Week 2011.

Uncontrolled SHPT On the Rise in Blacks Since Debut of 'Bundling'

Jody A. Charnow November 12, 2011

PHILADELPHIA—Uncontrolled secondary hyperparathyroidism (SHPT) has been on the increase among black hemodialysis (HD) patients since the recent implementation of the federal government's prospective payment system for dialysis services, researchers reported at Kidney Week 2011.

Untreated SHPT Increases Mortality Risk

Jody A. Charnow November 11, 2011

PHILADELPHIA—Untreated secondary hyperparathyroidism (SHPT) is associated with increased mortality risk in hemodialysis (HD) patients, according to a report presented at Kidney Week 2011.

Treating SHPT with Cinacalcet Lowers Phosphorus

Jody A. Charnow November 11, 2011

PHILADELPHIA—Serum phosphorus levels in hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT) decrease during treatment with cinacalcet, data presented at Kidney Week 2011 show. This effect occurs regardless of baseline SHPT severity.

Two Vitamin D Analogues Show Similar Efficacy for SHPT

Jody A. Charnow November 11, 2011

PHILADELPHIA—Alfacalcidol and paricalcitol have similar efficacy in suppressing secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients researchers reported at Kidney Week 2011.

Vitamin D Regimen May Treat SHPT in Renal Transplant Patients

Jody A. Charnow November 10, 2011

PHILADELPHIA—Cholecalciferol with or without doxercalciferol may be an appropriate treatment for secondary hyperparathyroidism (SHPT) in kidney transplant recipients, according to the findings of a small study presented at Kidney Week 2011.

High PTH and FGF-23 Predict Vascular Calcification

Jody A. Charnow November 10, 2011

PHILADELPHIA—Elevated levels of serum parathyroid hormone (PTH) and fibroblast growth factor-23 (FGF-23) are associated with an increased likelihood of progression of vascular calcification (VC) in hemodialysis patients, French researchers reported at Kidney Week 2011.

Study Identifies Predictors of Cinacalcet Use After Transplantation

Jody A. Charnow November 10, 2011

PHILADELPHIA—The dose of cinacalcet dialysis patients receive prior to renal transplantation and their time on dialysis appear to be the most important factors associated with reintroduction of the drug during the first year following transplantation, Spanish researchers reported at Kidney Week 2011.

Cinacalcet May Reduce ESA Use

Jody A. Charnow February 23, 2011

PHOENIX—Cinacalcet hydrochloride (CH) treatment in dialysis patients with secondary hyperparathyroidism may improve responsiveness to an erythropoiesis-stimulating agent (ESA) by reducing systemic inflammation, resulting in decreased ESA requirements, new data suggest.

Post-Transplant Cinacalcet May Be An Option

Jody A. Charnow November 02, 2010

Cinacalcet may be useful for treating hyperparathyroidism after renal transplantation, new findings suggest.

Mineral Metabolism Unaffected by Ergocalciferol

John Schieszer June 18, 2010

Weekly (50,000 units) and monthly doses (50,000 units) of ergocalciferol treatment does not significantly impact markers of mineral metabolism (MM) in chronic hemodialysis (HD) patients, a study suggests.

Thrice-Weekly Post-Dialysis Cinacalcet A Viable Option

John Schieszer June 18, 2010

New approach may ease problems with noncompliance, according to researchers.

SHPT Treatment May Have CAC Benefit

John Schieszer June 10, 2010

Cinacalcet plus low-dose vitamin D for secondary hyperparathyroidism yielded encouraging results

Polycystic Kidney Disease Affects PTH-Related Mortality

John Schieszer April 17, 2010

Very high and very low parathyroid hormone (PTH) levels are associated with the highest mortality rates in hemodialysis (HD) patients. However, a patient's level of risk may be related to whether the patient also has polycystic kidney disease (PKD), according to a study presented at the National Kidney Foundation's Spring Clinical Meetings.

Our exclusive coverage of Kidney Week 2011 in Philadelphia includes interviews, videos and noteworthy clinical reports.

Sections: Anemia | Transplantation
Secondary Hyperparathyroidism | General News
More: Videos

On The Forefront

Boosting Renal Transplantation with Kidney Paired Donation

In the past five to 10 years, researchers have developed several techniques to overcome donor incompatibility, including paired donation. The following case illustrates the collaborative efforts between nephrologists and urologists at the Glickman Urological and Kidney Institute.

Commentary

Kidney Stone Prevention: 'Fact versus Fiction'

According to current estimates, kidney stones will develop in 1 in 10 people during their lifetime. This translates to nearly 30 million people in the United States. Clearly, prevention is paramount.